BerGenBio

BerGenBio ASA - Key information relating to the reverse share split and change of ISIN

Bergen, Norway, 28 May 2024: Reference is made to the stock exchange

announcement published by BerGenBio ASA (the "Company") on 23 May 2023,

regarding the Company's annual general meeting resolving a reverse share split

of the Company's shares. Key information related to the reverse share split is

set out below:

· Reverse split ratio: 100:1, i.e. one hundred (100) old shares give one (1)

new share

· Date on which the corporate action was made public: 30 April 2024

· Date of approval: 23 May 2024 (AGM)

· Last day including right: 29 May 2024 (trading inclusive right of reverse

split)

· Ex-date: 30 May 2024 (trading exclusive right of reverse split)

· Record date: 31 May 2024

· New number of shares outstanding after reverse share split: 39,087,116

In connection with the reverse share split, the Company's shares will be

transferred to a new ISIN.

Please note the following key information for the change of ISIN:

· Issuer: BerGenBio ASA

· Previous ISIN: NO 001 0650013

· New ISIN: NO 001 3251173

· Date of ISIN change: 30 May 2024

For further information, please contact:

Martin Olin, CEO, BerGenBio ASA

Rune Skeie, CFO, BerGenBio ASA

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including cancer and severe respiratory infections. The

Company is focused on its proprietary lead candidate bemcentinib a potentially

first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC

and severe respiratory infections. BerGenBio is based in Bergen, Norway with a

subsidiary in Oxford, UK. The Company is listed on the Oslo Stock Exchange

(ticker: BGBIO). For more information, visit www.bergenbio.com.

This information is published in accordance with the requirements of the

Continuing Obligations pursuant to Oslo Rule Book II.

AI Terminal